197 related articles for article (PubMed ID: 21810839)
1. Micafungin therapy in a critically ill, morbidly obese patient.
Zomp A; Bookstaver PB; Ahmed Y; Turner JE; King C
J Antimicrob Chemother; 2011 Nov; 66(11):2678-80. PubMed ID: 21810839
[No Abstract] [Full Text] [Related]
2. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
5. Micafungin: new drug. Severe candidiasis: a third echinocandin, with life-threatening hepatotoxicity.
Prescrire Int; 2009 Aug; 18(102):154. PubMed ID: 19743568
[No Abstract] [Full Text] [Related]
6. In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
Bordallo-Cardona MÁ; Escribano P; de la Pedrosa EG; Marcos-Zambrano LJ; Cantón R; Bouza E; Guinea J
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872063
[TBL] [Abstract][Full Text] [Related]
7. Failure of echinocandin therapy in the treatment of Candida glabrata chorioretinitis.
Mousselli HA; Norwood J
Am J Med Sci; 2012 Jan; 343(1):98-100. PubMed ID: 22052412
[TBL] [Abstract][Full Text] [Related]
8. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
9. Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries.
Asensio MJ; Sánchez M; Galván B; Herrero E; Cachafeiro L; Agrifoglio A; Perales E; Luque S; García-de-Lorenzo A
Intensive Care Med; 2015 Feb; 41(2):371-2. PubMed ID: 25465909
[No Abstract] [Full Text] [Related]
10. [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients].
Pozo-Laderas JC
Rev Iberoam Micol; 2009 Mar; 26(1):69-74. PubMed ID: 19463281
[TBL] [Abstract][Full Text] [Related]
11. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
[TBL] [Abstract][Full Text] [Related]
12. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
13. Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis.
Mochizuki K; Suemori S; Udo K; Komori S; Ohkusu K; Yamada N; Ogura S
J Ocul Pharmacol Ther; 2011 Oct; 27(5):531-3. PubMed ID: 21751880
[TBL] [Abstract][Full Text] [Related]
14. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
Carter NJ; Keating GM
Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
[TBL] [Abstract][Full Text] [Related]
15. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.
Slater JL; Howard SJ; Sharp A; Goodwin J; Gregson LM; Alastruey-Izquierdo A; Arendrup MC; Warn PA; Perlin DS; Hope WW
Antimicrob Agents Chemother; 2011 Jul; 55(7):3075-83. PubMed ID: 21502627
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
17. The management of Candida infections in preterm neonates and the role of micafungin.
Manzoni P; Benjamin DK; Hope W; Rizzollo S; Del Sordo P; Stronati M; Jacqz-Aigrain E; Castagnola E; Farina D
J Matern Fetal Neonatal Med; 2011 Oct; 24 Suppl 2():24-7. PubMed ID: 21749182
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.
Saraya T; Tanabe K; Araki K; Yonetani S; Makino H; Watanabe T; Tsujimoto N; Takata S; Kurai D; Ishii H; Miyazaki Y; Takizawa H; Goto H
J Clin Microbiol; 2014 Jul; 52(7):2709-12. PubMed ID: 24789192
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
[TBL] [Abstract][Full Text] [Related]
20. Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report.
Yamada SM; Tomita Y; Yamaguchi T; Matsuki T
J Med Case Rep; 2016 Nov; 10(1):316. PubMed ID: 27821139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
